MarketCapExport financials
Acorda Therapeutics (ACOR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Acorda Therapeutics Income Statement 2023-2007 | ACOR
Brief overview of financial results at Acorda Therapeutics
The conclusions below are based on five years of reported results. Acorda Therapeutics reported revenue of $69.2 million in 2018 and $118 million by 2023. The total change was +70.1%, with a CAGR of approximately 11.2%. The company expanded its sales base at a healthy rate.
The gross result shifted from 47.7 million dollars to 102 million dollars, or +114.7%. Cost of revenue developed more favorably than sales, supporting gross profitability. At the margin level, the figure shifted from 68.9% to 87%. A wider margin shows that the economics of the core business improved.
The five-year EBITDA result moved by −566.9%: from 50 million dollars to −233 million dollars. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 72.3% at the start and −198.3% at the end. The business retained less EBITDA from each unit of revenue.
The net financial result changed from 9.6 million dollars to −253 million dollars. The move from profit to loss indicates a material deterioration in final efficiency.
Over the period, capitalization shifted from 4.7 billion dollars to 16.7 million dollars (−99.6%). Financial performance is stronger than the share-price trend.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The strongest signals are a larger revenue base and better sales economics. The most visible risks are declining net profitability, weaker operating efficiency and a weaker market valuation. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
16.7 M | 13.6 M | 19.6 M | 54.5 M | 96.6 M | 4.69 B | 7.16 B | 5.57 B | 9.33 B | 10.3 B | 7.08 B | 6.84 B | 5.97 B | - | - | - | - |
Shares |
1.24 M | 1.01 M | 10.6 M | 8.08 M | 7.93 M | 47 M | 46 M | 45.3 M | 42.2 M | 41.2 M | 40.2 M | 39.5 M | 39 M | 38.4 M | 37.7 M | - | - |
Historical Prices |
13.5 | 13.5 | 1.85 | 6.74 | 12.2 | 99.8 | 156 | 123 | 221 | 249 | 176 | 173 | 153 | - | - | - | - |
Net Income |
-253 M | -65.9 M | -104 M | -99.6 M | -273 M | 9.6 M | -223 M | -34.6 M | 11.1 M | 17.7 M | 16.4 M | 155 M | 30.6 M | -11.8 M | -83.9 M | -74.3 M | - |
Revenue |
118 M | 119 M | 129 M | 153 M | 192 M | 69.2 M | 588 M | 520 M | 493 M | 401 M | 336 M | 306 M | 292 M | - | - | - | - |
Cost of Revenue |
15.3 M | 30.3 M | 40.8 M | 33.5 M | 34.8 M | 97.6 M | 111 M | 107 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 119 M | 41.8 M | 47.7 M | 138 M | 110 M | 104 M | 92.7 M | 74.1 M | 65.1 M | 59.2 M | 53.9 M | - | - | - |
Operating Income |
-265 M | -35.3 M | -79 M | -78.1 M | -312 M | 38.5 M | -233 M | -36 M | 34 M | 36.4 M | 30.4 M | 25.6 M | 35.1 M | -8.43 M | -81.3 M | -73.4 M | - |
Interest Expense |
31.5 M | 30.2 M | 30 M | 30.6 M | 21.9 M | 21.6 M | 18.7 M | 16.5 M | 15.5 M | 9.29 M | 2.17 M | 1.88 M | 3.57 M | 3.92 M | -4.42 M | 5.59 M | - |
EBITDA |
-233 M | -2.53 M | -45.1 M | -36.8 M | -277 M | 50 M | -210 M | -14.4 M | 49 M | 44.9 M | 37.4 M | 30.3 M | 39.7 M | -4.48 M | -78.5 M | -70 M | - |
Operating Expenses |
- | - | - | 206 M | 279 M | 279 M | 348 M | 439 M | 459 M | 365 M | 306 M | 280 M | 257 M | 199 M | 136 M | 121 M | - |
General and Administrative Expenses |
89.7 M | 106 M | 124 M | 153 M | 193 M | 172 M | 182 M | 235 M | 206 M | 202 M | 186 M | 169 M | 149 M | 133 M | 89.9 M | 73.3 M | - |
All numbers in USD currency
Quarterly Income Statement Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.24 M | 1.24 M | 1.24 M | 24.3 M | - | 24.3 M | 16.8 M | 13.3 M | - | 11.1 M | 9.99 M | 9.47 M | - | 47.7 M | 47.7 M | 47.7 M | - | 47.5 M | 47.5 M | 47.5 M | - | 47.2 M | 46.8 M | 46.5 M | - | 46 M | 45.9 M | 45.8 M | 45.7 M | 45.4 M | 45.3 M | 44.8 M | 43 M | 42.2 M | 42.1 M | 42 M | 41.9 M | 41.1 M | 41 M | 40.9 M | 40.9 M | 40.3 M | 40 M | 39.8 M | 39.8 M | 39.5 M | 39.4 M | 39.3 M | 39.3 M | 39.1 K | 38.9 K | 38.8 M | 38.4 M | 38.4 M |
Net Income |
-27.4 M | -8.89 M | -9.38 M | -16.8 M | - | -13.9 M | -46.7 M | -24.5 M | - | -27.1 M | -22.9 M | -33.5 M | - | 7.35 M | -17.4 M | -6.47 M | 65.7 M | -264 M | -27.5 M | -47.6 M | 9.6 M | -13.9 M | 46.2 M | -8.2 M | -171 M | -25.2 M | -8.2 M | -18.9 M | -3.09 M | -12.7 M | -18.3 M | -520 K | 9.2 M | 3.94 M | 997 K | -3.08 M | 331 K | 12 M | 4.68 M | 703 K | 6.19 M | 7.48 M | 3.91 M | -1.14 M | 133 M | 9.59 M | 4.54 M | 7.85 M | 12.7 M | 18.9 M | -285 K | -672 K | 12.4 M | -6.76 M |
Revenue |
20.3 M | 27.7 M | 29.7 M | 22.3 M | - | 33.5 M | 31.1 M | 22.5 M | - | 31.5 M | 31.8 M | 28.9 M | - | 53.1 M | 33.6 M | 28.1 M | 50.5 M | 47.7 M | 50.1 M | 44.1 M | 69.2 M | 143 M | 153 M | 106 M | 188 M | 141 M | 139 M | 119 M | - | 136 M | 127 M | 116 M | - | 148 M | 114 M | 99.9 M | - | 106 M | 97.1 M | 80.5 M | - | 84.9 M | 87.1 M | 71.9 M | - | 77.4 M | 75.7 M | 71.2 M | - | 93 M | 65.3 M | 61.3 M | - | - |
Cost of Revenue |
3.71 M | 3.39 M | 3.06 M | 3.23 M | - | 11 M | 8.8 M | 5.97 M | - | 13.3 M | 11.3 M | 12 M | - | 12.2 M | 6.66 M | 3.84 M | - | 7.99 M | 9.4 M | 8.8 M | - | 25.4 M | 31.1 M | 20.6 M | - | 30 M | 29.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.8 M | 39.7 M | 40.7 M | 35.3 M | 47.7 M | 117 M | 122 M | 84.8 M | 138 M | 111 M | 110 M | 94 M | 110 M | 108 M | 101 M | 92.6 M | 104 M | 123 M | 90.8 M | 81.2 M | 92.7 M | 85.2 M | 78.1 M | 64.8 M | 74.1 M | 67.5 M | 70 M | 58.2 M | 65.1 M | 62.5 M | 61.9 M | 58.6 M | 59.2 M | 66.4 M | 53.2 M | 49.2 M | - | - |
Operating Income |
-19.6 M | -2.52 M | -3.63 M | -11.5 M | - | -4.99 M | -13.9 M | -16.7 M | - | -23 M | -15.7 M | -28.8 M | - | 16 M | -9.55 M | -6.17 M | - | -259 M | -23.4 M | -43.4 M | - | 28.3 M | 59 M | 454 K | - | -2.16 M | 2.7 M | -15.3 M | - | -5.47 M | -14 M | -17.2 M | - | 25.7 M | 5.69 M | -1.26 M | - | 20.8 M | 11 M | 3.42 M | - | 11.4 M | 8.74 M | -2.5 M | - | 10.4 M | 5.06 M | 8.86 M | - | 20.7 M | 920 K | 441 K | 13.3 M | -5.7 M |
Interest Expense |
8.44 M | 7.98 M | 7.77 M | 7.57 M | - | 7.46 M | 7.47 M | 7.56 M | - | 7.17 M | 7.7 M | 7.82 M | - | 7.76 M | 7.48 M | 7.57 M | - | 4.5 M | 5.38 M | 6.42 M | - | 5.42 M | 5.41 M | 5.5 M | - | 4.18 M | 5.46 M | 4.14 M | - | 4.4 M | 4.03 M | 3.72 M | - | 4.04 M | 4.01 M | 4.05 M | - | 4.6 M | 426 K | 92 K | - | 544 K | 749 K | 591 K | - | 373 K | 356 K | 766 K | - | 947 K | 1.28 M | 1.14 M | 944 K | 1.19 M |
EBITDA |
-18.7 M | 21.2 M | 12.2 M | -3.56 M | - | 19.8 M | 3.06 M | -8.17 M | - | 2.47 M | 1.47 M | -20.3 M | - | 47 M | 11.1 M | 3.91 M | - | -235 M | -8.51 M | -38.5 M | - | 37.4 M | 65.7 M | 3.76 M | - | 15.3 M | 14.4 M | -9.63 M | - | 10.3 M | -4.12 M | -13.2 M | - | 36.8 M | 13.2 M | 2.45 M | - | 26.2 M | 14.6 M | 5.18 M | - | 16 M | 11.7 M | -1.1 M | - | 13.4 M | 7.01 M | 9.77 M | - | 23.9 M | 3.1 M | 1.58 M | 16.1 M | -3.92 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 141 M | 141 M | 133 M | - | 123 M | 108 M | 101 M | - | 85.1 M | 86.2 M | 77.1 M | - | 73.5 M | 78.3 M | 74.4 M | - | 67.1 M | 70.6 M | 62.4 M | - | 72.4 M | 64.4 M | 60.8 M | 50.4 M | 48.5 M |
General and Administrative Expenses |
28.4 M | 23.2 M | 21.8 M | 22.5 M | - | 23 M | 30.1 M | 26.9 M | - | 29.6 M | 32.4 M | 34 M | - | 39.9 M | 38.7 M | 41.1 M | - | 48.7 M | 50.2 M | 52.7 M | - | 43.6 M | 44.3 M | 47.6 M | - | 40.7 M | 49.3 M | 52 M | - | 54.8 M | 62.6 M | 59 M | - | 51.1 M | 52.8 M | 48.8 M | - | 47.8 M | 50.6 M | 46.9 M | - | 42.3 M | 48 M | 48.2 M | - | 40.1 M | 44.2 M | 38.7 M | - | 34.7 M | 40.3 M | 38.1 M | 30.7 M | 34.1 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Acorda Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Daré Bioscience
DARE
|
$ 0.85 | 4.7 % | $ 9.5 M |  USA |
 |
DBV Technologies S.A.
DBVT
|
$ 11.76 | 1.82 % | $ 1.64 B |  France |
 |
DiaMedica Therapeutics
DMAC
|
$ 8.27 | 0.85 % | $ 389 M | USA |
 |
Denali Therapeutics
DNLI
|
$ 20.67 | 0.38 % | $ 3.57 B | USA |
 |
Precision BioSciences
DTIL
|
$ 6.26 | 1.29 % | $ 80.3 M | USA |
 |
Dyadic International
DYAI
|
$ 0.44 | 0.49 % | $ 15.9 M | USA |
 |
Editas Medicine
EDIT
|
$ 2.57 | 0.19 % | $ 228 M | USA |
 |
Edesa Biotech
EDSA
|
$ 4.21 | 18.26 % | $ 23.9 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.5 | 4.73 % | $ 22.8 M |  Israel |
 |
Enanta Pharmaceuticals
ENTA
|
$ 13.18 | 4.27 % | $ 281 K | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 2.91 | 8.18 % | $ 134 M | Israel |
 |
Equillium
EQ
|
$ 1.63 | 0.31 % | $ 93.4 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 51.49 | 0.02 % | $ 1.39 B | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.4 | 7.89 % | $ 3.15 M | Israel |
 |
Exelixis
EXEL
|
$ 58.41 | 0.91 % | $ 15.9 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
$ 3.27 | 3.32 % | $ 240 K | USA |
 |
Fate Therapeutics
FATE
|
$ 2.37 | 0.63 % | $ 282 M | USA |
 |
Fortress Biotech
FBIO
|
$ 2.14 | 1.38 % | $ 59.7 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 10.65 | 0.5 % | $ 304 M | USA |
|
Foghorn Therapeutics
FHTX
|
$ 3.57 | 1.42 % | $ 225 M | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.7 | 0.27 % | $ 234 M | USA |
 |
Galectin Therapeutics
GALT
|
$ 3.88 | 0.13 % | $ 248 M | USA |
 |
Geron Corporation
GERN
|
$ 1.23 | 0.81 % | $ 820 M | USA |
 |
Gilead Sciences
GILD
|
$ 149.05 | 0.85 % | $ 185 B | USA |
 |
Greenwich LifeSciences
GLSI
|
$ 18.05 | 2.07 % | $ 244 M | USA |
 |
Genmab A/S
GMAB
|
$ 35.67 | 0.3 % | $ 2.31 B |  Danmark |
 |
Genprex
GNPX
|
$ 2.92 | 2.46 % | $ 2.72 M | USA |
 |
Gossamer Bio
GOSS
|
$ 11.85 | 2.33 % | $ 2.71 B | USA |
 |
GeoVax Labs
GOVX
|
$ 0.33 | 0.28 % | $ 316 K | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.31 | 0.21 % | $ 4.97 B |  Spain |
 |
GlaxoSmithKline plc
GSK
|
$ 48.17 | 0.93 % | $ 195 B |  Britain |
 |
GT Biopharma
GTBP
|
$ 6.47 | 0.22 % | $ 35.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
$ 110.4 | 0.1 % | $ 13.2 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 14.63 | 3.39 % | $ 12.6 B |  China |
 |
Harmony Biosciences Holdings
HRMY
|
$ 39.26 | 0.1 % | $ 2.26 B | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.31 | 2.45 % | $ 51.7 M | USA |
 |
iBio
IBIO
|
$ 1.18 | 0.85 % | $ 123 M | USA |
 |
ImmuCell Corporation
ICCC
|
$ 9.8 | 0.61 % | $ 88.5 M | USA |
 |
IDEAYA Biosciences
IDYA
|
$ 38.42 | 1.48 % | $ 3.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.8 | 0.54 % | $ 121 M |  Germany |
 |
Inhibikase Therapeutics
IKT
|
$ 2.06 | 1.73 % | $ 203 M | USA |
 |
Immutep Limited
IMMP
|
$ 4.65 | 0.21 % | $ 6.77 B |  Australia |
 |
Immunome
IMNM
|
$ 21.51 | 0.41 % | $ 1.88 B | USA |
 |
Immuron Limited
IMRN
|
$ 1.16 | 2.59 % | $ 268 M | Australia |
|
Immatics N.V.
IMTX
|
$ 8.78 | 2.57 % | $ 1.07 B | Germany |
 |
Immunic
IMUX
|
$ 9.3 | 4.38 % | $ 1.45 B | USA |
 |
Immunovant
IMVT
|
$ 33.78 | 0.96 % | $ 6.16 B | USA |
 |
Incyte Corporation
INCY
|
$ 121.35 | 0.06 % | $ 23.7 B | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.36 | 0.06 % | $ 5.66 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.95 | 0.56 % | $ 48.3 M | USA |